Long-Term cardio- and cerebrovascular events in patients with primary aldosteronism

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 12, 2013, Pages 4826-4833

  Mulatero, Paolo ^a   Monticone, Silvia ^a   Bertello, Chiara ^a   Viola, Andrea ^a   Tizzani, Davide ^a   Iannaccone, Andrea ^a   Crudo, Valentina ^a   Burrello, Jacopo ^a   Milan, Alberto ^a   Rabbia, Franco ^a   Veglio, Franco ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MINERALOCORTICOID ANTAGONIST;

ADRENAL HYPERPLASIA; ADRENALECTOMY; ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DISEASE DURATION; ESSENTIAL HYPERTENSION; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

ADRENAL GLANDS; ADRENOCORTICAL ADENOMA; ADULT; AGING; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CEREBROVASCULAR DISORDERS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERALDOSTERONISM; HYPERPLASIA; HYPERTENSION; INCIDENCE; ITALY; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; STROKE;

EID: 84889845942     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2805     Document Type: Article

References (28)

1. Mulatero P, Milan A, Williams TA, Veglio F. Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovasc Hematol Agents Med Chem. 2006;4:75-91.
2. Funder JW. Minireview: Aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinology. 2006;147:5564- 5567.
3. Verhovez A, Williams TA, Monticone S, et al. Genomic and nongenomic effects of aldosterone. Curr Sign Transd Ther. 2012;7:132- 141.
4. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci. 2002;970:89-100.
5. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243- 1248.
6. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168:80-85.
7. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: A controlled crosssectional study. Hypertension. 2013;62:331-336.
8. Born-Frontsberg E, Reincke M,RumpLC, et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: Results of the German Conn's Registry. J Clin Endocrinol Metab. 2009;94:1125-1130.
9. Mulatero P, Milan A, Fallo F, et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab. 2006;91:2618-2623.
10. Mulatero P, Bertello C, Sukor N, et al. Impact of different diagnostic criteria during adrenal vein sampling on reproducibility of subtype diagnosis in patients with primary aldosteronism. Hypertension. 2010;55:667-673.
11. Mulatero P, Bertello C, Rossato D, et al. Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. J Clin Endocrinol Metab. 2008;93:1366-1371.
12. Mulatero P, Bertello C, Verhovez A, et al. Differential diagnosis of primary aldosteronism subtypes. Curr Hypertens Rep. 2009;11: 217-223.
13. Mulatero P, Morello F, Veglio F. Genetics of primary aldosteronism. J Hypertens. 2004;22:663-670.
14. Catena C, Colussi G, Marzano L, Sechi LA. Aldosterone and the heart: from basic research to clinical evidence. Horm Metab Res. 2012;44:181-187.
15. Mulatero P, Monticone S, Rainey WE, Veglio F, Williams TA. Role of KCNJ5 in familial and sporadic primary aldosteronism. Nat Rev Endocrinol. 2013;9:104-112.
16. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol. 2012;350:256-265.
17. Leibovitz E, Ebrahimian T, Paradis P, Schiffrin EL. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. J Hypertens. 2009;27:2192-2200.
18. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab. 2001;12:308- 314.
19. Maule S, Mulatero P, Milan A, et al. QT interval in patients with primary aldosteronism and low-renin essential hypertension. J Hypertens. 2006;24:2459-2464.
20. .Young MJ, Rickard AJ. Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis. Mol Cell Endocrinol. 2012;350:248-255.
21. Ouvrard-Pascaud A, Sainte-Marie Y, Bénitah JP, et al. Conditional mineralocorticoid receptor expression in the heart leads to lifethreatening arrhythmias. Circulation. 2005;111:3025-3033.
22. Reil JC, Hohl M, Selejan S, et al. Aldosterone promotes atrial fibrillation. Eur Heart J. 2012;33:2098-2108.
23. Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol. 2012; 350:266-272.
24. Funder JW. Aldosterone, hypertension and heart failure: Insights from clinical trials. Hypertens Res. 2010;33:872-875.
25. Reincke M, Meisinger C, Holle R, et al. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn's Registry. Horm Metab Res. 2010;42:435-439.
26. Whaley-Connell A, Sowers Jr. Aldosterone and risk for insulin resistance. Hypertension. 2011;58:998-1000.
27. Williams TA, Monticone S, Urbanet R, et al. Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. Mol Cell Endocrinol. 2012;355:162-168.
28. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150:776-783